Patents Assigned to Boehringer Ingelheim Pharma GmbH & Co. KG
  • Patent number: 8466271
    Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: June 18, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co, KG
    Inventor: Barbara Enenkel
  • Publication number: 20130140351
    Abstract: The invention relates to a folding box made from a one-piece cardboard blank (28) comprising an integrally formed hinged lid (7) that overlaps an upper end area of a rectangular-cuboid-shaped body (1) on three sides, is connected to a rear wall (5) of the body (1) through a fold line (6), and lies flush on a front wall (4) and two side walls (3) in the closed state, and having a front panel (9) and two side panels (10) that form a collar (11) that protrudes into the hinged lid (7), wherein the front panel (9) is arranged parallel to and at a distance from the front wall (4) and divides the body (1) into a main compartment (12) and a front compartment (13).
    Type: Application
    Filed: January 30, 2013
    Publication date: June 6, 2013
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Reinhard SCHULD
  • Publication number: 20130116435
    Abstract: The invention relates to a new process for preparing tiotropium salts of general formula 1 wherein X? may have the meanings given in the claims and in the specification.
    Type: Application
    Filed: December 27, 2012
    Publication date: May 9, 2013
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Boehringer Ingelheim Pharma GmbH & Co. KG
  • Patent number: 8431585
    Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: April 30, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Thomas Singer, Stefan Platz, Florian Colbatzky
  • Patent number: 8420630
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 16, 2013
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Patent number: 8409611
    Abstract: A process which can be used in the laboratory or on an industrial scale for cleaning the inner wall of hard gelatine capsules, in which the sealed capsules are cleaned with a powder formulation.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: April 2, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Herbert Wachtel, Petra Schmidt-Joerg, Volker Freudenberger
  • Patent number: 8349615
    Abstract: The invention relates to a method of finding suitable parameters for the chromatographic purification of biomolecules. The method consists of equilibration, charging, washing and eluting steps, this sequence of steps being carried out by the partial batch method. The parameters determined in small, preferably numerous parallel test batches provide conclusions as to the chromatography conditions under which a given biomolecule can be purified optimally by column chromatography, optionally even on a larger scale.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: January 8, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Christian Eckermann, Sybille Ebert, Stefanie Rubenwolf, Dorothee Ambrosius
  • Patent number: 8343982
    Abstract: The present invention relates methods for treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder by administration to a patient in need thereof of a therapeutically effective amount of a bicyclic heterocyclic groups of general formula wherein said substituents are as defined herein.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: January 1, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Birgit Jung, Flavio Solca
  • Publication number: 20120329778
    Abstract: The present invention relates to bicyclic heterocycles of general formula wherein Ra to Rc, A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
    Type: Application
    Filed: September 5, 2012
    Publication date: December 27, 2012
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Thomas METZ, Flavio SOLCA, Birgit JUNG, Anke BAUM
  • Patent number: 8338179
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: December 25, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Publication number: 20120296091
    Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 22, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Peter SIEGER, Dirk KEMMER, Peter KOHLBAUER, Thomas NICOLA, Martin RENZ
  • Publication number: 20120285451
    Abstract: The invention relates to novel two-piece metal capsules for accommodating pharmaceutical preparations to be used in powder inhalers as well as a method for producing said capsule. The inventive capsules are particularly impermeable to steam and oxygen.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 15, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventor: Dieter HOCHRAINER
  • Patent number: 8298575
    Abstract: The present invention relates to capsules for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to their use in powder inhalers. The capsules consist of water-insoluble hydrophobic synthetic materials which do not significantly affect the pharmaceutical quality of the contents themselves, but which improve the usability of the filled capsules with regard to their function, their longevity, and/or the geographic location of their use, and are advantageous at various stages from manufacture up to utilization.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: October 30, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dieter Hochrainer, Josef Eckert
  • Publication number: 20120263787
    Abstract: A method of sealing parts of a plastic capsule by forming a weld seam in an overlapping region of the parts of the capsule, wherein the capsule comprises a capsule cap having an open end and a capsule body having an open end, and capsules formed by such method. The capsules produced by the process according to the invention are disposable and preferably contain a single dose of a pharmaceutical formulation in the form of a powder or liquid intended to be administered by inhalation and are suitable by their form and function for use in powder inhalers or liquid nebulizers for producing aerosols. Aerosols thus produced can be inhaled, for example, in order to administer a pharmaceutical formulation to the lungs.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 18, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Dieter HOCHRAINER, Herbert WACHTEL
  • Patent number: 8281784
    Abstract: A mouthpiece for an inhaler for administering a drug in the form of substances, substance formulations or substance mixtures that can be inhaled comprises an inhalation channel (4) for coupling to a chamber for receiving the drug. At least one component (10) having an aerodynamic cross-section is arranged in the inhalation channel (4).
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: October 9, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Herbert Wachtel
  • Publication number: 20120252782
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf R.H. LOTZ
  • Patent number: 8263788
    Abstract: The invention relates to a method for producing 1,3-dioxolane-2-ones of general formula (3) in basic reaction conditions by reesterifying the respective ester of general formula (1) in which R1 to R5 have the meanings indicated in the claims and the description. The invention further relates to a method for producing 2-hydroxy carboxylic acid esters of general formula (5) with or without isolation of the intermediate in the form of a derivative of the 1,3-dioxolane-2-one of general formula (3) in basic reaction conditions by reesterifying the respective ester of general formula (1) in which R1, R2, and R6 have the meanings indicated in the claims and the description. The method according to the invention allows the reaction to take place in very gentle basic conditions, causing fewer secondary reactions and providing a greater yield than reactions in highly polar aprotic solvents. Acid-sensitive and/or temperature-sensitive compounds can be synthesized.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: September 11, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Joerg Brandenburg, Rolf Dach, Hanfried Baltes
  • Publication number: 20120211007
    Abstract: An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1, ?{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 ?m, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 ?m to 500 ?m, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 ?{square root over (kPa)} min/L containing the inhalable powder.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 23, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventor: Bernd ZIERENBERG
  • Publication number: 20120208831
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: April 17, 2012
    Publication date: August 16, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Matthias ECKHARDT, Michael MARK, Roland MAIER, Ralf R. H. LOTZ, Mohammad TADAYYON
  • Publication number: 20120189556
    Abstract: A pharmaceutical composition comprising an anticholinergic and a steroid, optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the steroid optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.
    Type: Application
    Filed: March 29, 2012
    Publication date: July 26, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Michel PAIRET, Michael P. PIEPER, Christopher John Montague MEADE, Richard REICHL, Christel SCHMELZER